For Immediate Release
Managing the Complexities and Risks of HIV and Tuberculosis Coinfection
Contact: Kathryn Ryan
New Rochelle, NY, October 18, 2018—A new study identified a significant association between HIV infection and complexities of treating patients with tuberculosis coinfection. Patients with HIV were more likely to have more tuberculosis drug-related adverse events, more hospital readmissions, and longer tuberculosis treatment duration, as reported in AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the AIDS Research and Human Retroviruses website through November 18, 2018.
Marcos Schechter, Emory University School of Medicine (Atlanta, GA) and colleagues from the Rollins School of Public Health, Emory University (Atlanta, GA), Emory University, Fulton County Health Board of Health (Atlanta), DeKalb County Board of Health (Decatur, GA), and Grady Memorial Hospital (Atlanta, GA) coauthored the article entitled “Treatment Complexities among Patients with Tuberculosis in a High HIV Prevalence Cohort in the United States.” The researchers demonstrated a more complex treatment course for patients with tuberculosis in an area with a high rate of HIV coinfection and emphasized the importance of having the resources and expertise to treat coinfected patients in these areas.
“This study demonstrates that infection with HIV and TB worsens the course of multiple clinically relevant aspects of TB care, increasing hospital readmissions, and adverse events and duration of drug treatment. This knowledge will help clinicians provide better and more efficient treatment for the many individuals coinfected with HIV and TB around the world,” says Thomas Hope, PhD, Editor-in-Chief of AIDS Research and Human Retroviruses and Professor of Cell and Molecular Biology at Northwestern University, Feinberg School of Medicine, Chicago, IL.
Research reported in this publication was supported by the National Institutes of Health under Award Numbers K23AI103044, R21AI122001, UL1TR000454, and UL1TR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About the Journal
AIDS Research and Human Retroviruses, published monthly online with open access options and in print, presents papers, reviews, and case studies documenting the latest developments and research advances in the molecular biology of HIV and SIV and innovative approaches to HIV vaccine and therapeutic drug research, including the development of antiretroviral agents and immune-restorative therapies. Content also explores the molecular and cellular basis of HIV pathogenesis and HIV/HTLV epidemiology. The Journal features rapid publication of emerging sequence information, reports on clinical trials of emerging HIV therapies, and images in HIV research. Tables of content and a sample issue may be viewed on the AIDS Research and Human Retroviruses website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including AIDS Patient Care and STDs, Viral Immunology, and Journal of Interferon and Cytokine Research. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.